Registered title, quoted from ClinicalTrials.gov
AI-Guided First-Line Immunotherapy Selection in Unresectable Hepatocellular Carcinoma
An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Tongji Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07729618, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 3
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (3 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Hepatocellular carcinoma confirmed by histology or cytology, or diagnosed using accepted noninvasive radiologic criteria.
Inclusion criterion 2
Eastern Cooperative Oncology Group performance status of 0 or 1.
Inclusion criterion 6
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07729618, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age 18 years or older.
- Hepatocellular carcinoma confirmed by histology or cytology, or diagnosed using accepted noninvasive radiologic criteria.
- Unresectable hepatocellular carcinoma for which first-line systemic therapy is indicated, including Barcelona Clinic Liver Cancer stage B disease that is unsuitable for or no longer benefiting from locoregional therapy, or stage C disease.
- No prior systemic anticancer therapy for unresectable hepatocellular carcinoma.
- Child-Pugh class A liver function.
- Eastern Cooperative Oncology Group performance status of 0 or 1.
- Eligible and intended to receive at least one protocol-specified, guideline-concordant immune checkpoint inhibitor-based first-line regimen, as determined by the treating clinician before exposure to the study AI recommendation.
- Eligibility confirmed and prospective participant registration completed before the final first-line treatment regimen is selected.
- Baseline contrast-enhanced computed tomography or magnetic resonance imaging suitable for assessment according to Response Evaluation Criteria in Solid Tumors version 1.1 is available before initiation of first-line systemic therapy.
- Required pretreatment clinical data are available within the protocol-specified assessment windows.
- Able to provide written informed consent.
Exclusion Criteria:
- Known combined hepatocellular-cholangiocarcinoma or another primary liver malignancy other than hepatocellular carcinoma.
- A contraindication or clinical condition that makes all protocol-specified immune checkpoint inhibitor-based first-line regimens inappropriate according to applicable prescribing information and routine clinical practice.
- Initiation of systemic therapy or completion of the final first-line regimen decision before prospective participant registration.
- Exposure of the treating clinical team to the participant-specific AI recommendation before confirmation of eligibility and registration.
- Concurrent anticancer treatment for another malignancy that would materially interfere with treatment selection or study outcome assessment.
- Planned participation in another interventional study that dictates first-line systemic treatment or would interfere with study outcome assessment.
- Inability to undergo protocol-required tumor imaging or follow-up assessments.
Quoted from ClinicalTrials.gov, NCT07729618, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07729618, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.